Kevin Boyle Senior: I can assure you that manufacturing has never been a rate-limiting step whatsoever. We have a very strong manufacturing platform and/or simply building up the throughput capacity for anticipation of the enrollment to come. We all long anticipated that until we had an early data release, that enrollment might be at a slower pace than we would like. But we are now very excited with the proffer talk at CICON, the confirmed partial response at the lowest dose level is really building momentum. There have been a few patients that, unfortunately, these are patients that have just very tragic diseases with heavy disease burden. And as a result, there were patients that did match the HLA and TCR mutation — the TCRs, but unfortunately, had other exclusion criteria, because of their worsening their health declining at a fast pace.
So it’s unfortunate that when other therapies failed them, they did not meet the inclusion criteria from a health perspective, even though they matched one of our TCRs. And so what we are excited about with the two new TCRs coming in with the move from fresh to cryopreserved product, we believe that we will be able to produce cells even earlier in a patient’s journey, which will allow us to, we believe, treat more patients and I can tell you that the excitement, we have a lot of inbound inquiries, people coming from different geographies, people responding to the our presentation of that that of the case studies mentioned at CRADA and NCI. So, again, a reminder, three different TCRs on our clinical trial have now been clinically validated by having confirmed partial responses.
So there we are very excited about the prospect of enrolling and treating many more patients in 2023 and anticipate the treatment pattern to increase quite dramatically.
Thomas Flaten: I appreciate all that color. And just to confirm for me, and perhaps, I missed it, how many patients do you anticipate treating at dose Level 2 assuming no DLTs or ICANS?
Kevin Boyle Senior: We are going to let the science speak for itself there. So we are going to follow very closely working with the PIs to determine that. So we will certainly update as we go along.
Thomas Flaten: Excellent. Appreciate you guys taking the questions. Thank you.
Kevin Boyle Senior: Thank you.
Operator: Our next question comes from the line of Chris Howerton with Jefferies. Chris, your line is now open.
Unidentified Analyst: Hi. This is Antea for Chris Howerton. Sorry about the audio issue earlier. Thank you for taking our questions and congratulations on a great quarter. We have two questions. First, is there any differences in the purity and viability of the TCR-T cells using the cryopreserved process? And second, what tumor types are you expecting to dose in your next patient and what the next data cut will be? Thank you.
Kevin Boyle Senior: Abhi?
Abhi Srivastava: Thank you for question. Let me start by saying that first two patients, when we look at characteristics of these two different cells, there is really high liability, purity and TCR positivity that we compare with fresh versus cryopreserve products based on our early few qualification around. We do not see any differences in terms of the better dispositions, we still maintain the same amount of liability, purity and TCR positivity.
Kevin Boyle Senior: Great. And we have not disclosed what the indication will be from those patients ahead. We do anticipate presenting additional data in 2023 at a major medical conference, and at that time, they are much more translational data on the patients that we have and share additional information about the indication. So, again, we do reiterate that we have six different solid tumor indications that we are treating with our Phase 1/2 basket trial.
Unidentified Analyst: Got it. Thank you for taking our questions.
Kevin Boyle Senior: Thank you.
Abhi Srivastava: Thank you.
Operator: I am showing no further questions in queue at this time. This concludes today’s conference call. Thank you for participating. You may now…